What Kintara Therapeutics does

Kintara Therapeutics Inc. was a publicly traded clinical-stage biopharmaceutical company focused on developing therapies for cancer patients, headquartered in Vancouver, Canada, and incorporated in the United States. The company built its pipeline around two distinct drug candidates: REM-001, a photodynamic therapy that uses light-activated compounds to selectively destroy cancer cells in cutaneous metastatic breast cancer lesions, and VAL-083, a chemotherapy agent for cancer treatment. Both assets were in clinical development, with REM-001 supported by a $2.0 million NIH SBIR grant awarded in June 2023 to generate clinical evidence for a Phase 3 study design.

The company's business model was pre-commercial: Kintara generated no product revenue and instead funded operations through a combination of equity financing (notably a $20 million committed share purchase agreement with Lincoln Park Capital in August 2022) and non-dilutive grants. Its GTM motion consisted of scientific conference presentations, press releases, and regulatory filings rather than traditional sales channels, and distribution was planned for post-approval through pharmaceutical channels.

In December 2025, REM-001 met its primary safety endpoint in a clinical trial, triggering the release of contingent value right (CVR) shares and confirming the company's acquisition by TuHURA Biosciences. Prior to that, Kintara had pursued pipeline expansion through acquisitions, including Adgero Biopharmaceuticals in June 2020, and operated with a lean team of 1-10 employees. The acquisition transitioned Kintara from an independent public entity into a wholly-controlled subsidiary of TuHURA Biosciences.

Name

Kintara Therapeutics

Legal name

Kintara Therapeutics Inc.

Website

https://kintara.com

Company type

Public

Founded year

2010

Operating status

Acquired

Headcount range

1–10 employees

Short description

Kintara Therapeutics was a pre-revenue, publicly traded clinical-stage biopharmaceutical company developing REM-001 photodynamic therapy for cutaneous metastatic breast cancer and VAL-083 chemotherapy, acquired by TuHURA Biosciences in December 2025.

Ownership category

akta.pro rank

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Marketing channels2 records

Core offering

Kintara Therapeutics is a clinical-stage biopharmaceutical company developing two cancer drug candidates: REM-001, a photodynamic therapy designed to treat cutaneous metastatic breast cancer, and VAL-083, a chemotherapy agent under development for cancer treatment. Both assets are in the clinical pipeline, with REM-001 advancing toward a Phase 3 study following NIH SBIR grant support.

Product overview

Kintara Therapeutics is a biopharmaceutical company developing two distinct cancer therapies. REM-001 is a photodynamic therapy in clinical development for cutaneous metastatic breast cancer, recently supported by a $2.0 million NIH SBIR grant to generate clinical evidence for a Phase 3 study. VAL-083 is a chemotherapy agent also under development for cancer treatment. Both products are in the clinical development pipeline and have received funding support, including a $20 million equity financing agreement with Lincoln Park Capital for working capital and development expenses.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• REM-001 met primary safety endpoint in clinical trial (December 2025)

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• TuHURA BiosciencescoreStrategic or Co-development PartnerFollowing Kintara's merger/acquisition by TuHURA Biosciences, Kintara's REM-001 clinical trial met its primary safety endpoint in December 2025, resulting in the release of contingent value rights (CVR) shares. Approximately 1.54 million shares of TuHURA stock were distributed to legacy Kintara stockholders as a result of this milestone achievement.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Onxeo: Clinical-stage oncology biopharma developing novel therapeutics including a photodynamic therapy asset (Validive). Comparable in modality, stage, and small-cap profile to Kintara.
• Photocure: Commercial-stage photodynamic therapy company (Hexvix/Cysview) for bladder cancer. Closest pure-play peer in the PDT oncology space, sharing the same light-activated mechanism as REM-001.
• Steba Biotech: Developer of Tookad, a vascular-targeted photodynamic therapy for prostate cancer. Direct PDT modality peer with similar mechanism and oncology focus.
• Theralase Technologies: Clinical-stage company developing photodynamic therapy (TLD-1433) for non-muscle invasive bladder cancer. Direct PDT peer with comparable small-cap clinical-stage profile.
• Soligenix: Late-stage clinical biopharma developing oncology and rare disease therapeutics. Comparable as a small clinical-stage biotech with limited headcount and dual-asset pipeline.
• Moleculin Biotech: Clinical-stage oncology biotech developing small-molecule therapies for hard-to-treat tumors. Comparable in scale, stage, and pre-revenue clinical development model.
• Cardiff Oncology: Clinical-stage oncology company developing small-molecule therapies with a lead asset in metastatic colorectal cancer. Similar pre-revenue clinical profile and small-cap public status.
• Verastem Oncology: Small-cap oncology biotech developing kinase inhibitors for hematologic cancers and solid tumors. Comparable as a publicly traded clinical-stage oncology company of similar size.

Others

• Lumenis (LightMed/Biolitec): Medical laser technology company whose devices enable photodynamic therapy delivery. Enabler/adjacent company providing infrastructure for PDT procedures like REM-001.

Broad incumbents

• Mirati Therapeutics: Established targeted oncology biotech (acquired by Bristol-Myers Squibb) developing small-molecule oncology therapies. Comparable modality (targeted small molecules) at later commercial stage.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/delmarpharma
• Facebookfacebook.com/delmarpharma
• LinkedInlinkedin.com/company/delmar-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds13 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kintara Therapeutics